"Global Royalty Financing Deals in Pharma, Biotech and Diagnostics 2010-2015" Published

The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2005-2015 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2005 to early 2015.

Full Report Details at
- http://www.fastmr.com/prod/1006739_global_royalty_financing.aspx?afid=301

The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all partnering deals announced since 2005 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2005. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2005, including a summary of the recent literature on the subject.

Chapter 3 provides an average benchmark royalty rates. The chapter includes numerous tables and figures summarizing the benchmark royalty rates by stage of development, therapy area and technology area.

Chapter 4 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal. The chapter includes numerous case studies for actual deals where royalty rates have been disclosed.

Chapter 5 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates, and why.

Chapter 6 provides comprehensive and detailed access to deals which disclose a royalty rate since 2005 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2015
- Licensing Terms and Agreements in Pharma, Biotech and Diagnostics
- Diagnostics Partnering Terms and Agreements
- Global Companion Diagnostics Partnering 2010-2015 : Deal trends, players, financials and forecasts
- Global Personalized Medicine Partnering 2010-2015: Deal trends, players, financials and forecasts